Table 3.
Trials by therapeutic category
| NUMBER OF TRIALS BY THERAPEUTIC CATEGORY | ||||||||
| Category | Phase 1 | Phase 2 | Phase 3 | TOTAL | ||||
| Anti-inflammatories | 3 | 6.4% | 0 | 0.0% | 0 | 0.0% | 3 | 2.2% |
| Antioxidants | 1 | 2.1% | 2 | 2.8% | 1 | 5.0% | 4 | 2.9% |
| Cell therapy | 10 | 21.3% | 2 | 2.8% | 0 | 0.0% | 12 | 8.6% |
| Dopaminergic symptom relief - DA agonist | 7 | 14.9% | 1 | 1.4% | 6 | 30.0% | 14 | 10.1% |
| Dopaminergic symptom relief - LD reformulation | 3 | 6.4% | 2 | 2.8% | 3 | 15.0% | 8 | 5.8% |
| Dopaminergic symptom relief - other | 5 | 10.6% | 1 | 1.4% | 1 | 5.0% | 7 | 5.0% |
| Energy and mitochondria | 0 | 0.0% | 3 | 4.2% | 0 | 0.0% | 3 | 2.2% |
| GBA | 1 | 2.1% | 2 | 2.8% | 0 | 0.0% | 3 | 2.2% |
| GLP-1 agonists | 0 | 0.0% | 4 | 5.6% | 1 | 5.0% | 5 | 3.6% |
| Kinase inhibitors | 1 | 2.1% | 3 | 4.2% | 0 | 0.0% | 4 | 2.9% |
| LRRK2 | 1 | 2.1% | 1 | 1.4% | 1 | 5.0% | 3 | 2.2% |
| Microbiome/GIT | 4 | 8.5% | 3 | 4.2% | 1 | 5.0% | 8 | 5.8% |
| Neurotrophic factors | 2 | 4.3% | 1 | 1.4% | 0 | 0.0% | 3 | 1.4% |
| Non-dopaminergic symptom relief - Adrenergic | 0 | 2.1% | 3 | 4.2% | 1 | 5.0% | 4 | 2.9% |
| Non-dopaminergic symptom relief - Cholinergic | 0 | 0.0% | 3 | 2.8% | 2 | 10.0% | 5 | 3.6% |
| Non-dopaminergic symptom relief - NMDA | 0 | 0.0% | 7 | 9.9% | 0 | 0.0% | 7 | 5.0% |
| Non-dopaminergic symptom relief - Serotoninergic | 1 | 2.1% | 8 | 11.3% | 1 | 5.0% | 10 | 7.2% |
| Non-dopaminergic symptom relief - other | 1 | 2.1% | 12 | 16.9% | 0 | 0.0% | 13 | 9.4% |
| Targeting alpha- synuclein | 6 | 12.8% | 6 | 8.5% | 2 | 10.0% | 14 | 10.1% |
| Other DMT | 1 | 2.1% | 8 | 11.3% | 0 | 0.0% | 9 | 6.5% |
| TOTAL | 47 | 100% | 72 | 100% | 20 | 100% | 139 | 100% |